AstraZeneca PLC (AZN) Stock

Healthcare · Drug Manufacturers - General · Member of Other US Stocks

AstraZeneca PLC (AZN) closed at USD 162.03 on 2026-10-14, a change of -0.9 % over the past year, with a market capitalization of USD 258.5B.

AstraZeneca PLC recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

AstraZeneca PLC key figures

Previous close

USD 162.03 (2026-10-14)

1-year change

-0.9 %

Market cap

USD 258.5B

Enterprise value

USD 285.98B

P/E ratio (trailing)

23.95

P/E ratio (forward)

14.69

EPS (trailing)

6.96

EPS (forward)

11.34

PEG ratio

1.14

Price to book

5.14

Revenue growth

6.4 %

Earnings growth

2.5 %

Dividend per share (trailing)

3.23

Short ratio

0.88

Employees

96,100

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies for rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of oral candidates, with the potential to treat diseases across multiple indications; Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates; and Carterra, Inc. to advances lab-in-the-loop drug discovery through new scientific research collaboration. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for AstraZeneca PLC and compare it with other stocks.